Literature DB >> 16803861

Utilization of combined chemical modifications to enhance the blood-brain barrier permeability and pharmacological activity of endomorphin-1.

Hong-Mei Liu1, Xue-Feng Liu, Jin-Long Yao, Chang-Lin Wang, Ye Yu, Rui Wang.   

Abstract

The endogenous mu-opioid receptor agonist, endomorphin (EM)-1, cannot be delivered into the central nervous system (CNS) in sufficient quantity to elicit analgesia when given systemically because it is severely restricted by the blood-brain barrier (BBB). To improve the physicochemical characteristics of EM-1 and subsequently achieve greater BBB permeation, we synthesized a series of EM-1 analogs by combining successful chemical modifications, including N-terminal cationization, C-terminal chloro-halogenation, and unnatural amino acid (d-Ala, Sar, and d-Pro-Gly) substitutions in position 2. Presently, their binding and bioassay activity, lipophilicity, stability, and antinociceptive activity were determined and compared. Guanidino-addition and chloro-halogenation attenuated the mu-receptor affinity to some extent, but they demonstrated differences in the influence on stability. It appeared that guanidino-addition contributed to brain stability enhancement for the greater part, whereas chloro-halogenation together with amino acid substitutions in position 2 was of more importance for the stability enhancement in serum than in brain. Determination of the octanol/buffer coefficient revealed that chloro-halogenation did compromise the decreased lipophilicity caused by guanidino-addition, and introduction of d-Ala as well as d-Pro-Gly, but not Sar, in place of l-Pro(2), also increased the overall lipophilicity to some extent. Among the peptides tested, intracerebroventricular injection of guanidino-[d-Ala(2), p-Cl-Phe(4)]EM-1 showed the strongest analgesia, being 3 times more potent than the parent peptide. We also found that in comparison with EM-1, the four d-Ala-containing tetrapeptides and the chloro-halogenated d-Pro-Gly-containing pentapeptide elicited significant and prolonged central-mediated analgesia upon subcutaneous administration, indicating that more peptides reached the CNS, eliciting greater analgesic effect.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16803861     DOI: 10.1124/jpet.106.106484

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

Review 1.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

Review 2.  Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging.

Authors:  Sonu Bhaskar; Furong Tian; Tobias Stoeger; Wolfgang Kreyling; Jesús M de la Fuente; Valeria Grazú; Paul Borm; Giovani Estrada; Vasilis Ntziachristos; Daniel Razansky
Journal:  Part Fibre Toxicol       Date:  2010-03-03       Impact factor: 9.400

Review 3.  Engineering endomorphin drugs: state of the art.

Authors:  Lawrence H Lazarus; Yoshio Okada
Journal:  Expert Opin Ther Pat       Date:  2012-01-04       Impact factor: 6.674

4.  Effect of anchoring 4-anilidopiperidines to opioid peptides.

Authors:  Ravil R Petrov; Yeon Sun Lee; Ruben S Vardanyan; Lu Liu; Shou-wu Ma; Peg Davis; Josephine Lai; Frank Porreca; Todd W Vanderah; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2013-04-03       Impact factor: 2.823

5.  Development of PACAP38 analogue with improved stability: physicochemical and in vitro/in vivo pharmacological characterization.

Authors:  Satomi Onoue; Junko Hanato; Kazuki Kuriyama; Takahiro Mizumoto; Shizuo Yamada
Journal:  J Mol Neurosci       Date:  2010-06-29       Impact factor: 3.444

6.  Opioid Peptides: Potential for Drug Development.

Authors:  Jane V Aldrich; Jay P McLaughlin
Journal:  Drug Discov Today Technol       Date:  2012

7.  N-terminal guanidinylation of TIPP (Tyr-Tic-Phe-Phe) peptides results in major changes of the opioid activity profile.

Authors:  Grazyna Weltrowska; Thi M-D Nguyen; Nga N Chung; Brian C Wilkes; Peter W Schiller
Journal:  Bioorg Med Chem Lett       Date:  2013-07-23       Impact factor: 2.823

8.  An efficient synthesis of indolo[2,3-b]quinoline guanidine derivatives with their in vitro and in vivo study.

Authors:  Katarzyna Sidoryk; Marta Świtalska; Piotr Rózga; Joanna Wietrzyk; Iwona Bujak; Bartłomiej Żerek; Łukasz Kaczmarek; Marcin Cybulski
Journal:  Med Chem Res       Date:  2017-09-05       Impact factor: 1.965

Review 9.  Impact of non-proteinogenic amino acids in the discovery and development of peptide therapeutics.

Authors:  Yun Ding; Joey Paolo Ting; Jinsha Liu; Shams Al-Azzam; Priyanka Pandya; Sepideh Afshar
Journal:  Amino Acids       Date:  2020-09-18       Impact factor: 3.520

Review 10.  Nanoscale Drug Delivery Systems in Glioblastoma.

Authors:  Zihao Liu; Xiaoshuai Ji; Dong He; Rui Zhang; Qian Liu; Tao Xin
Journal:  Nanoscale Res Lett       Date:  2022-02-16       Impact factor: 5.418

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.